Effect of aspirin and ticlopidine on plasma tissue factor levels in stable and unstable angina pectoris.
Patients with unstable angina have an increased activation of the coagulation system. Aspirin and ticlopidine given in combination may potentiate each other by the combination of different action mechanisms and may reduce the risk of coronary occlusion and clinical instability. Plasma tissue factor (TF) levels collected into the stenotic coronary artery may be an index of TF expression within the vasculature. In 160 patients undergoing angioplasty for a 81+/-5% coronary lesion, we measured TF in blood samples collected from a vein and from the coronary ostium. Immediately after and 10 minutes after the dilation procedures the samples were withdrawn also beyond the lesion. Heparin 150 U/kg was given as an anticoagulant. All patients were pretreated with 250 mg/day of aspirin. One hundred twenty patients were randomly assigned to receive 24, 48, or 72 hours of ticlopidine treatment (250 mg/twice daily). TF levels did not increase during angioplasty but there was a significantly higher TF expression in unstable than in stable patients, irrespective of the invasiveness of debulking procedures. When ticlopidine was given for 72 hours, TF levels were similar to normal laboratory values both in stable and unstable patients. This combined antiplatelet pretreatment may be of benefit in unstable angina patients, with a favorable cost/benefit ratio.
Marco
J
J
Clinique Pasteur, Toulouse, France.
Ariëns
R A
RA
Fajadet
J
J
Bossi
I M
IM
Marco
I
I
Bernies
M
M
Romano
S M
SM
Donatelli
F
F
Brambilla
G M
GM
Somalvico
F
F
Mari
D
D
Gregorini
L
L
D000787:Angina Pectoris / Q000097:blood / Q000188:drug therapy* / Q000628:therapy; D000789:Angina, Unstable / Q000097:blood / Q000188:drug therapy* / Q000628:therapy; D015906:Angioplasty, Balloon, Coronary; D000990:Antithrombin III / Q000378:metabolism; D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use*; D017225:Atherectomy, Coronary; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010447:Peptide Hydrolases / Q000378:metabolism; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011292:Premedication; D015607:Stents; D013925:Thromboplastin / Q000187:drug effects / Q000378:metabolism*; D013988:Ticlopidine / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors
D010975:Platelet Aggregation Inhibitors; C046193:antithrombin III-protease complex; D000990:Antithrombin III; D013925:Thromboplastin; D010447:Peptide Hydrolases; D013988:Ticlopidine; D001241:Aspirin